Analyst Serge Belanger from Needham maintained a Buy rating on Ocular Therapeutix and keeping the price target at $18.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Serge Belanger has given his Buy rating due to a combination of factors centered on Axpaxli’s regulatory path and OCUL’s broader clinical catalysts. He views the first-quarter update as largely routine, with the key value driver now being the planned NDA submission for Axpaxli, which will rely on the 52‑week SOL‑1 trial data and ongoing discussions with the FDA.
Belanger also highlights additional upside from the continuing SOL‑R study, with top-line results expected in the first quarter of 2027, and from upcoming phase 3 wet AMD readouts (LUGANO and LUCIA) from EYPT beginning around mid‑2026. Reflecting this pipeline and the anticipated regulatory developments, he reiterates his Buy rating and keeps his price target unchanged at $18.
According to TipRanks, Belanger is a 5-star analyst with an average return of 13.4% and a 50.60% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Esperion, and Cormedix.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.